BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients

Launched by THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY · Nov 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different conditioning treatments for patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) who are undergoing a special type of stem cell transplant called allogeneic hematopoietic stem cell transplantation (allo-HSCT). The two treatments being compared are total body irradiation with chemotherapy (TBI-Cy) and a chemotherapy regimen called busulfan plus cyclophosphamide (BuCy). The goal is to see which method works better for improving survival rates and reducing side effects for patients, particularly in those who are children, have more severe disease, or have specific health conditions.

To participate in this trial, patients must be between the ages of 2 and 55, have T-ALL, and be receiving their first allo-HSCT. They should be able to understand the study and agree to participate by signing an informed consent form. Patients will be monitored throughout the trial to see how they respond to the treatment and to track any side effects. This study is important because it aims to find a safer and more effective way to treat T-ALL, which can be challenging to overcome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. T-ALL patients aged \> 2 years and ≤55 years;
• • 2. For the first time accept allo-HSCT;
• • 3. With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3; 4. Signing an informed consent form, having the ability to comply with study and follow-up procedures.
• Exclusion Criteria:
• • 1. With other malignancies;
• • 2. With a previous history of autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation or chimeric antigen receptor T cell therapy;
• • 3. With uncontrolled infection intolerant to haploidentical hematopoietic cell transplantation;
• • 4. With severe organ dysfunction;
• • 5. In pregnancy or lactation period;
• • 6. With any conditions not suitable for the trial (investigators' decision).